Marker Therapeutics (MRKR) Short-Term Debt issuances (2012 - 2016)

Marker Therapeutics (MRKR) reported Short-Term Debt issuances of -$25000.0 for Q1 2016, down 5100.0% quarter-over-quarter from $500.0 in Q1 2014.

Marker Therapeutics (MRKR) Short-Term Debt issuances (2012 - 2016) Analysis & Trends

Marker Therapeutics (MRKR) has 3 years of Short-Term Debt issuances data on file, last reported at -$25000.0 in Q1 2016.

  • Short-Term Debt issuances for Q1 2016 came in at -$25000.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2016 was -$25000.0 (down 5100.0% YoY), and the FY2016 annual result was -$25000.0, changed N/A from the prior year.
  • Short-Term Debt issuances retreated to -$25000.0 in Q1 2016 per MRKR's latest filing, from $500.0 in the prior quarter.
  • Over five years, Short-Term Debt issuances peaked at $3000.0 in Q3 2012 and troughed at -$25000.0 in Q1 2016.
  • A 3-year average of -$9875.0 and a median of -$8750.0 in 2012 frame the typical range for Short-Term Debt issuances.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Short-Term Debt issuances (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - -
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn -
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -33,000.00
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - -
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn -
9 Abivax 90.15 Bn 90.15 Bn - -
10 Marker Therapeutics 26.85 Mn 26.85 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2016 -25,000.00
Mar 31, 2016 -25,000.00
Mar 31, 2014 500.00
Mar 31, 2014 500.00
Dec 31, 2012 -18,000.00
Dec 31, 2012 -18,000.00
Sep 30, 2012 3,000.00
Sep 30, 2012 3,000.00